CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) was upgraded by equities research analysts at StockNews.com to a "sell" rating in a research report issued to clients and investors on Thursday.

Several other research firms also recently commented on CRSP. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada reissued a "sector perform" rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Truist Financial decreased their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $74.94.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock traded up $1.16 during mid-day trading on Thursday, hitting $51.88. 1,597,105 shares of the company traded hands, compared to its average volume of 1,456,449. CRISPR Therapeutics has a one year low of $43.42 and a one year high of $91.10. The stock has a market cap of $4.41 billion, a price-to-earnings ratio of -16.06 and a beta of 1.67. The stock has a fifty day moving average price of $47.38 and a 200-day moving average price of $52.24.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the previous year, the firm earned ($1.41) earnings per share. Sell-side analysts predict that CRISPR Therapeutics will post -5.57 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CRSP. Global Trust Asset Management LLC lifted its position in shares of CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company's stock valued at $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC raised its holdings in shares of CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company's stock valued at $33,000 after acquiring an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $35,000. Finally, Denver PWM LLC bought a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $45,000. Institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.